Cartesian Therapeutics Management
Management criteria checks 1/4
We currently do not have sufficient information about the CEO.
Key information
Carsten Brunn
Chief executive officer
US$7.3m
Total compensation
| CEO salary percentage | 8.79% |
| CEO tenure | 7yrs |
| CEO ownership | 0.1% |
| Management average tenure | 1.5yrs |
| Board average tenure | 4.5yrs |
Recent management updates
Recent updates
Cartesian: Maintaining Buy Rating For Expansion Of Descartes-08 For Myositis
Nov 17We Think Cartesian Therapeutics (NASDAQ:RNAC) Can Afford To Drive Business Growth
Oct 04
Subdued Growth No Barrier To Cartesian Therapeutics, Inc. (NASDAQ:RNAC) With Shares Advancing 27%
May 04Cartesian Therapeutics, Inc.'s (NASDAQ:RNAC) Popularity With Investors Under Threat As Stock Sinks 27%
Mar 18Cartesian Therapeutics: Need To Wait For More Data For Its Novel mRNA Therapies
Jan 17Risks Still Elevated At These Prices As Cartesian Therapeutics, Inc. (NASDAQ:RNAC) Shares Dive 33%
Jan 05Cartesian Therapeutics: Uncertainty Remains
Nov 10Cartesian Therapeutics Seems A 'Strong Buy' After Positive Phase 2 Results
Sep 17Cartesian: Further Value To Be Unlocked After Positive MG Treatment Data
Jul 02CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Sep 30 2025 | n/a | n/a | -US$48m |
| Jun 30 2025 | n/a | n/a | -US$36m |
| Mar 31 2025 | n/a | n/a | -US$40m |
| Dec 31 2024 | US$7m | US$643k | -US$77m |
| Sep 30 2024 | n/a | n/a | -US$282m |
| Jun 30 2024 | n/a | n/a | -US$267m |
| Mar 31 2024 | n/a | n/a | -US$288m |
| Dec 31 2023 | US$6m | US$618k | -US$257m |
Compensation vs Market: Carsten's total compensation ($USD7.31M) is above average for companies of similar size in the US market ($USD1.45M).
Compensation vs Earnings: Carsten's compensation has increased whilst the company is unprofitable.
CEO
Carsten Brunn (55 yo)
Dr. Carsten Brunn, Ph.D. serves as President, Chief Executive Officer & Chairman of the Board since October 29, 2025 and was Director of Cartesian Therapeutics, Inc. since December 2018 until October 29, 2...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 7yrs | US$7.31m | 0.12% $ 202.0k | |
| Chief Financial Officer | 3.1yrs | US$3.97m | 0.047% $ 81.6k | |
| Consultant | less than a year | US$2.71m | 0.10% $ 179.9k | |
| Chief Operating Officer | less than a year | no data | 0.13% $ 219.9k | |
| Chief Accounting Officer | less than a year | no data | no data | |
| General Counsel & Secretary | no data | no data | no data | |
| Chief Medical Officer | 2.1yrs | no data | 0.010% $ 18.0k |
Experienced Management: RNAC's management team is not considered experienced ( 1.5 years average tenure), which suggests a new team.
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 7yrs | US$7.31m | 0.12% $ 202.0k | |
| Independent Director | 9.4yrs | US$291.52k | 0.18% $ 319.4k | |
| Lead Independent Director | 8.5yrs | US$294.97k | 0.015% $ 25.5k | |
| Director | 9.5yrs | US$277.33k | 37.01% $ 64.3m | |
| Independent Director | 4.5yrs | US$284.97k | 0.0085% $ 14.8k | |
| Director | no data | no data | no data | |
| Independent Director | 1.4yrs | US$314.57k | 0% $ 0 | |
| Independent Director | 2.1yrs | US$280.81k | 19.45% $ 33.8m | |
| Independent Director | 2.1yrs | US$281.03k | 0.92% $ 1.6m |
Experienced Board: RNAC's board of directors are considered experienced (4.5 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/12/28 02:55 |
| End of Day Share Price | 2025/12/26 00:00 |
| Earnings | 2025/09/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Cartesian Therapeutics, Inc. is covered by 10 analysts. 9 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Julian Harrison | BTIG |
| John Newman | Canaccord Genuity |
| Kristen Kluska | Cantor Fitzgerald & Co. |